Drugs / HC010
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07477743 | Mar 2026 → Dec 2027 expected | — | HC Biopharma Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07381829 | Oct 2025 → Dec 2026 expected | — | HC Biopharma Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06307925 | Mar 2024 → Dec 2025 overdue | neoplasm | HC Biopharma Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07169552 | Dec 2025 → Dec 2026 expected | non-small cell lung carcinoma | HC Biopharma Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HC010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07477743 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06307925 ↗ |